What this means
Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity. Weight gain and clinical obesity exacerbate cardiovascular-kidney-metabolic health complications in this population and chronic weight management strategies that reduce these risks are now an urgent priority.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- Earlier studies
- Kind of research
- A summary of earlier studies
The science
- Original title
- Weight management in people with HIV.
- Authors
- Manne-Goehler J, Magodoro I, Ramírez BC et al.
- Journal
- The lancet. HIV
- Published
- Nov 8, 2026
- Study type
- Review
- PMID
- 43000036 ↗
Abstract
Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity. Weight gain and clinical obesity exacerbate cardiovascular-kidney-metabolic health complications in this population and chronic weight management strategies that reduce these risks are now an urgent priority. Behavioural interventions can be offered to improve diet and increase physical activity, including increasing protein intake and promoting regular physical activity. Additionally, there is a growing body of evidence to support the use of GLP-1 receptor agonist therapies in people with HIV, along with a historical literature showing the efficacy of tesamorelin; however, there are sparse data to direct the use of other approved obesity management medicines specific to this population. Finally, bariatric surgical interventions are suggested to be safe and efficacious for those with chronic HIV infection and comorbid obesity. This Series paper identifies a range of key evidence gaps and research priorities for obesity management in people with HIV, including a lack of trials of GLP-1 therapies in people with HIV powered to key clinical outcomes, such as major adverse cardiovascular events and body composition endpoints, implementation science to define models of care, and research on the heterogeneities in clinical outcomes of obesity treatment by sex.
Manne-Goehler J, Magodoro I, Ramírez BC et al. Weight management in people with HIV. The lancet. HIV. 2026. doi:10.1016/S2352-3018(26)00229-8. PMID: 43000036. https://pubmed.ncbi.nlm.nih.gov/43000036/
Related research
Aging exacerbates muscle loss induced by semaglutide treatment in female mice.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.
Review compares six collagen fillers for face loss linked to weight-loss drugs
This review looked at 43 studies of six types of collagen-building fillers and how each may signal cells. It does not show which filler works best, and no study tested people on these drugs.
Aging exacerbates muscle loss induced by semaglutide treatment in female mice
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.
A skin serum showed visible improvements in older women over 12 weeks
Women aged 45 and older used a facial serum twice a day for 12 weeks. Experts and participants saw changes in fine lines, wrinkles, and skin hydration. This study had no comparison group, so it cannot show the serum caused the changes.
Doctors' group offers a guide for using weight-loss drugs like GLP-1 in older adults
Experts wrote a guide on weighing benefits and risks, such as muscle loss, when older adults take these drugs. It is advice built from example patient cases, not a new study testing the drugs.
Tesamorelin reduced belly fat in people with HIV and fat changes
Four trials with 909 people found tesamorelin lowered belly fat and waist size. Long-term safety and how long the benefit lasts are still unclear.
See all research on GLP-1 drugs →
